Related Experiment Video
Updated: May 12, 2026

08:09
Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope
Published on: March 24, 2017
Structural and functional studies of Peptide-carbohydrate mimicry
Margaret A Johnson1, B Mario Pinto
1Department of Molecular Biology, The Scripps Research Institute, 10550 North Torrey Pines Rd., MB-44, 92037, La Jolla, CA, USA, maggie@scripps.edu.
Topics in Current Chemistry
|April 23, 2013
Summary
Certain peptides mimic carbohydrates, offering potential as vaccines and therapeutics. Structural studies reveal the molecular basis of this mimicry, guiding the design of new carbohydrate-mimetic drugs.
Area of Science:
- Carbohydrate chemistry
- Structural biology
- Immunology
Background:
- Peptides can mimic carbohydrates, binding to carbohydrate-binding proteins like lectins and antibodies.
- These peptide mimics (mimotopes) hold potential for vaccine and therapeutic development.
- However, binding does not always equate to desired biological activity, necessitating further biochemical validation.
Purpose of the Study:
- To review recent structural studies on peptide-carbohydrate mimicry.
- To explore the molecular basis of mimicry using various structural and biochemical techniques.
- To discuss implications for designing novel carbohydrate-mimetic therapeutics.
Main Methods:
- Nuclear Magnetic Resonance (NMR) spectroscopy
- X-ray crystallography
- Molecular modeling
- Biochemical assays
Main Results:
- Structural studies provide molecular-level insights into peptide-carbohydrate mimicry.
- The degree of structural mimicry required for biological activity is a key consideration.
- Comparisons with protein and glycopeptide mimics highlight different mimicry strategies.
Conclusions:
- Understanding the structural basis of mimicry is crucial for developing effective peptide-based therapeutics.
- Further research can optimize peptide design for specific biological activities.
- Peptide mimics offer a promising avenue for novel vaccine and drug development.

